These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 18976298)

  • 1. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.
    Locke JE; Magro CM; Singer AL; Segev DL; Haas M; Hillel AT; King KE; Kraus E; Lees LM; Melancon JK; Stewart ZA; Warren DS; Zachary AA; Montgomery RA
    Am J Transplant; 2009 Jan; 9(1):231-5. PubMed ID: 18976298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.
    Orandi BJ; Zachary AA; Dagher NN; Bagnasco SM; Garonzik-Wang JM; Van Arendonk KJ; Gupta N; Lonze BE; Alachkar N; Kraus ES; Desai NM; Locke JE; Racusen LC; Segev DL; Montgomery RA
    Transplantation; 2014 Oct; 98(8):857-63. PubMed ID: 25121475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody.
    Ghirardo G; Benetti E; Poli F; Vidal E; Della Vella M; Cozzi E; Murer L
    Pediatr Transplant; 2014 Feb; 18(1):E1-5. PubMed ID: 24266980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports.
    Kocak B; Arpali E; Demiralp E; Yelken B; Karatas C; Gorcin S; Gorgulu N; Uzunalan M; Turkmen A; Kalayoglu M
    Transplant Proc; 2013 Apr; 45(3):1022-5. PubMed ID: 23622614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
    Burbach M; Suberbielle C; Brochériou I; Ridel C; Mesnard L; Dahan K; Rondeau E; Hertig A
    Transplantation; 2014 Nov; 98(10):1056-9. PubMed ID: 24839895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Splenic Irradiation for the Treatment of Severe Antibody-Mediated Rejection.
    Orandi BJ; Lonze BE; Jackson A; Terezakis S; Kraus ES; Alachkar N; Bagnasco SM; Segev DL; Orens JB; Montgomery RA
    Am J Transplant; 2016 Oct; 16(10):3041-3045. PubMed ID: 27214874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering antibody-mediated rejection: new insights into mechanisms and treatment.
    Stegall MD; Gloor JM
    Curr Opin Organ Transplant; 2010 Feb; 15(1):8-10. PubMed ID: 19890210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosing Eculizumab for Antibody-Mediated Rejection in Kidney Transplantation: A Case Report.
    Smith B; Kumar V; Mompoint-Williams D; Reed RD; MacLennan PA; Stegner K; Locke JE
    Transplant Proc; 2016 Nov; 48(9):3099-3105. PubMed ID: 27932156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab for Treatment of Refractory Antibody-Mediated Rejection in Kidney Transplant Patients: A Single-Center Experience.
    Yelken B; Arpalı E; Görcin S; Kocak B; Karatas C; Demiralp E; Turkmen A
    Transplant Proc; 2015; 47(6):1754-9. PubMed ID: 26293046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.
    Stegall MD; Diwan T; Raghavaiah S; Cornell LD; Burns J; Dean PG; Cosio FG; Gandhi MJ; Kremers W; Gloor JM
    Am J Transplant; 2011 Nov; 11(11):2405-13. PubMed ID: 21942930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience.
    Slatinska J; Honsova E; Burgelova M; Slavcev A; Viklicky O
    Ther Apher Dial; 2009 Apr; 13(2):108-12. PubMed ID: 19379149
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant.
    Stewart ZA; Collins TE; Schlueter AJ; Raife TI; Holanda DG; Nair R; Reed AI; Thomas CP
    Transplant Proc; 2012 Dec; 44(10):3033-6. PubMed ID: 23195021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports.
    González-Roncero F; Suñer M; Bernal G; Cabello V; Toro M; Pereira P; Angel Gentil M
    Transplant Proc; 2012 Nov; 44(9):2690-4. PubMed ID: 23146495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement blockade with eculizumab to treat acute symptomatic humoral rejection after heart transplantation.
    Yerly P; Rotman S; Regamey J; Aubert V; Aur S; Kirsch M; Hullin R; Pascual M
    Xenotransplantation; 2022 Jan; 29(1):e12726. PubMed ID: 35001433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sequential administration of anti-complement component C5 eculizumab and type-2 anti-CD20 obinutuzumab for the treatment of early antibody-mediated rejection after kidney transplantation: A proof of concept.
    Favi E; Cresseri D; Perego M; Ikehata M; Iesari S; Campise MR; Morello W; Testa S; Sioli V; Mattinzoli D; Longhi E; Del Gobbo A; Castellano G; Ferraresso M
    Clin Immunol; 2024 Jul; 264():110240. PubMed ID: 38734036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody-mediated rejection despite inhibition of terminal complement.
    Bentall A; Tyan DB; Sequeira F; Everly MJ; Gandhi MJ; Cornell LD; Li H; Henderson NA; Raghavaiah S; Winters JL; Dean PG; Stegall MD
    Transpl Int; 2014 Dec; 27(12):1235-43. PubMed ID: 24990476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeated cycles of high-dose intravenous immunoglobulin and plasmapheresis for treatment of late antibody-mediated rejection of renal transplants.
    Lee CY; Lin WC; Wu MS; Yang CY; Yeh CC; Tsai MK
    J Formos Med Assoc; 2016 Oct; 115(10):845-852. PubMed ID: 27542515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of simultaneous acute antibody-mediated rejection and acute cellular rejection with alemtuzumab in kidney transplantation: a case report.
    Jirasiritham S; Khunprakant R; Techawathanawanna N; Jirasiritham S; Mavichak V
    Transplant Proc; 2010 Apr; 42(3):987-9. PubMed ID: 20430222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.